---
title: "Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer"
slug: "tailoring-adjuvant-endocrine-therapy-for-premenopausal-breast-cancer"
date: "2023-10-25"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[Suppression of Ovarian Function Trial]]

# Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

- premenopausal estrogen-receptor-positive breast cancer
- Extending the duration of tamoxifen treatment to 10 years further improves outcomes
- 他收了五千七百多個病人，把病人分在兩組中：一組走SOFT一組走TEXT
- 主要就是比較Tamoxifen alone / + OFS / + [[Exemestane]]

![Figure: height:450px](https://i.imgur.com/7poJ2Zr.png)

## Disease-free Survival among All Patients and According to HER2 and Chemotherapy Status in SOFT

![Figure: height:450px](https://i.imgur.com/GczwIF9.png)

- 從圖表看起來，在用Tamoxifen 的 → 病人中
  - HER2 negative, Chemotherapy 有或沒做，都有跨過一， ∴ 所以可能 ✖ 不一定有幫助
- 而用了Exemestane + OFS 比較 TAM alone的 → 病人中
  - 反而是HER2 positive 的 → 幫助比較有限
- 但一起看，以HR的 → 數值看起來，Exemestane 看起來比較有效
